Dr. Vaqar Ali, MD
Interventional Cardiology (Interventional Cardiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,391
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
FL license ME93151 -
Cardiovascular Disease Physician
FL license ME93151 -
Specialist
FL license ME93151
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- HCA Florida Memorial Hospital Jacksonville, FL
- HCA Florida Putnam Hospital Palatka, FL
Medical groups
- First Coast Cardiovascular Institute, LLC (45 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,391
- Services billed
- 7,984
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7,180 | 85 |
| Established patient office or other outpatient visit, 30-39 minutes | 674 | 425 |
| Ultrasound of leg arteries or artery grafts | 307 | 280 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 288 | 286 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 279 | 251 |
| Ultrasound of one leg arteries or artery grafts | 261 | 194 |
| Ultrasound of both sides of head and neck blood flow | 216 | 208 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 184 | 184 |
| Established patient office or other outpatient visit, 20-29 minutes | 151 | 142 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 141 | 137 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 83 payments worth $7,720 in total to this clinician.
| Abbott Laboratories | $3,151 |
|---|---|
| Endologix LLC | $2,988 |
| Edwards Lifesciences Corporation | $215 |
| Imperative Care, Inc | $214 |
| Cvrx, Inc. | $202 |
| Abiomed | $147 |
| Amgen Inc. | $137 |
| Actelion Pharmaceuticals US, Inc. | $116 |
| Travel and Lodging | $2,519 |
|---|---|
| Food and Beverage | $2,451 |
| Speaking at a medical education program | $1,650 |
| Consulting Fee | $1,100 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Abbott Laboratories Jun 24, 2025 | Speaking at a medical education program XACT · Structural Heart | $1,650 |
| Abbott Laboratories Jun 24, 2025 | Consulting Fee XACT · Structural Heart | $1,100 |
| Endologix LLC Apr 5, 2025 | Travel and Lodging ENDOCROSS Device; Torus Stent Graft System · Cardiology/Vascular Diseases · travel to Santa Rosa, CA · in-kind | $822 |
| Endologix LLC Apr 22, 2025 | Travel and Lodging ENDOCROSS Device; Torus Stent Graft System · Cardiology/Vascular Diseases · travel to Santa Rosa, CA · in-kind | $764 |
| Endologix LLC Apr 5, 2025 | Travel and Lodging Torus Stent Graft System; ENDOCROSS Device · Cardiology/Vascular Diseases · travel to Santa Rosa, CA · in-kind | $455 |
| Endologix LLC Apr 3, 2025 | Travel and Lodging ENDOCROSS Device; Torus Stent Graft System · Cardiology/Vascular Diseases · travel to Santa Rosa, CA · in-kind | $249 |
| Endologix LLC Mar 11, 2025 | Travel and Lodging travel to Santa Rosa, CA · in-kind | $150 |
| Endologix LLC Apr 4, 2025 | Travel and Lodging ENDOCROSS Device; Torus Stent Graft System · Cardiology/Vascular Diseases · travel to Santa Rosa, CA · in-kind | $35.25 |
| Endologix LLC Apr 4, 2025 | Travel and Lodging Torus Stent Graft System; ENDOCROSS Device · Cardiology/Vascular Diseases · travel to Santa Rosa, CA · in-kind | $33.00 |
| Endologix LLC Mar 11, 2025 | Travel and Lodging travel to Santa Rosa, CA · in-kind | $11.20 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $27,432 in research payments for these studies, mostly to the institutions running them.
- A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR 018 Drug Eluting Balloon in the Treatment of Subjects With Femoropopliteal Artery Lesions
M.a. Med Alliance S.a. - NCT03309332--AMPLATZER PFO Occluder Post Approval Study
Abbott Laboratories - A Prospective Randomized Single Blind Multicenter Study to Assess the Safety and Effectiveness of the SELUTION SLR 014 Drug Eluting Balloon in the Treatment of Subjects With In-stent Restenosis
M.a. Med Alliance S.a.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.